BeiGene's Brukinsa poised to lead CLL market

31 January 2023

A rosy future is predicted for Sino-American biotech BeiGene (HKEX: 06160) oral Bruton tyrosine kinase inhibitor (BTKi) Brukinsa (zanubrutinib), which recently gained US Food and Drug Administration (FDA) approval for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL).

Brukinsa has gained approval after outperforming AbbVie’s (NYSE: ABBV) Imbruvica (ibrutinib), which has been the standard of care in CLL for almost a decade. Brukinsa should largely replace Imbruvica as the preferred regimen and will more often be used as a treatment for patients who’ve relapsed, according to analytics company GlobalData.

In the Phase III ALPINE study, Brukinsa showed superior progression-free survival (hazard ratio [HR]: .65) and a significantly lower incidence of cardiovascular adverse events compared to Imbruvica.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Biotechnology